Seventhly, in the context that “triple-negative” (negative for JAK2V617F, CALR, and MPL-mutations) ET patients have a much more favourable prognosis than mutation-positive ET patients, some triple-negative “ET” patients may actually not have a MPNs but instead polyclonal inflammation-driven thrombocythemia. The gene discussed is CALR; the disease is essential thrombocythemia.